πŸ‡ΊπŸ‡Έ FDA
Patent

US 7534913

Crystalline form of nateglinide

granted A61KA61K31/16A61K31/198

Quick answer

US patent 7534913 (Crystalline form of nateglinide) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K31/16, A61K31/198, A61P, A61P3/00